Oral Dalfampridine Extended Release Tablets in Patients with Multiple
Sclerosis
Trial Status
Open for Enrollment
What is the Purpose of this Study?
To investigate the evaluate the safety
and efficacy of two doses ( 5 mg and 10 mg twice daily) of oral Dalfampridine
extended release in patients with MS
Who is Eligible to Participate?
Patients 18-70 years of age who have
MS-related walking impairment. Patients must be off Betaseron, Estavia,
Avonex, Copazone, Rebif, Tysabri or Gilenya 90 days prior to screening.
Patients must also meet all other inclusion and exclusion criteria explained
in detail by study coordinator.
What is involved in this Study?
Patients will be randomized to a 1:1:1
treatment fashion to either extended release dalfampridine 5 mg twice
daily, 10 mg twice daily or matching placebo. Patients will have walking
tests and questionnaires throughout the study.
How long is the Study?
All patients will undergo 4 weeks of study treatment.
The total study duration is approximately 5 weeks.
For More Information Contact: Lynne E. Flynn, CCRC, study coordinator,
at 602-258-2863 or lynneflynn@pnal.net or call the Main line at 602-258-3354
